Abstract
Skeletal muscle ischemia is a major consequence of peripheral arterial disease (PAD) or critical limb ischemia (CLI). While therapeutic options for resolving muscle ischemia in PAD/CLI are limited, the issue is compounded by poor understanding of the mechanisms driving muscle vascularization. We found that nuclear receptor estrogen-related receptor alpha (ERRα) expression is induced in murine skeletal muscle by hindlimb ischemia (HLI) and in cultured myotubes by hypoxia, suggesting a potential role for ERRα in ischemic response. To test this, we generated skeletal muscle-specific ERRα transgenic (TG) mice. In these mice, ERRα drives myofiber type switch from glycolytic type IIB to oxidative type IIA/IIX myofibers, which are typically associated with more vascular supply in muscle. Indeed, RNA sequencing and functional enrichment analysis of TG muscle revealed that ‘paracrine angiogenesis’ is the top-ranked transcriptional program activated by ERRα in the skeletal muscle. Immunohistochemistry and angiography showed that ERRα overexpression increases baseline capillarity, arterioles and non-leaky blood vessel formation in the skeletal muscles. Moreover, ERRα overexpression facilitates ischemic neo-angiogenesis and perfusion recovery in hindlimb musculature of mice subjected to HLI. Therefore, ERRα is a hypoxia inducible nuclear receptor that is involved in skeletal muscle angiogenesis and could be potentially targeted for treating PAD/CLI.
Keywords: Nuclear receptors, Gene Expression, Ischemia, Angiogenesis, Skeletal muscle
INTRODUCTION
Skeletal muscle ischemia arises from the occlusion or regression of blood vessels perfusing the limb musculature (1, 2). Impaired perfusion and ischemia in the limb muscles, is the central pathology of vascular complications such as peripheral arterial disease (PAD) and critical limb ischemia (CLI), resulting in leg pain and immobility, or in severe cases limb amputations (1–3). Prevalence of PAD has dramatically increased with estimated rise to over 200 million cases worldwide (4). Major effort has been placed on discovering therapeutic approaches to promote skeletal muscle revascularization in PAD. However, targeting angiogenic factors such as Vegfa and Fgf1 individually have not yielded clinically effective pharmacological approaches (5). As a result, there are limited medications for PAD/CLI, and alternatives such as endovascular surgeries for restoring perfusion are expensive and not always successful. Therefore, there is an urgent need to extend our understanding of molecular pathways that regulate skeletal muscle vascularization. Particularly, signaling within the skeletal muscle that can drive tissue vascularization in a paracrine fashion is poorly understood, and warrants further investigation.
Adult skeletal muscle is a plastic tissue that can adapt through metabolic and vascular remodeling in response to inactivity, physical training and disease (6–8). Adaptive changes are orchestrated by transcriptional factors, among which nuclear receptors have emerged as leading regulators of skeletal muscle function (9, 10). For example, members of the PPAR family – PPARα and PPARδ – are involved in transcriptional induction of fatty acid and/or glucose metabolism, mitochondrial biogenesis, oxidative phosphorylation and slow-twitch oxidative myofibers in the skeletal muscle, and can influence insulin and glucose homeostasis in diabetes and obesity (11–15). Estrogen-related receptors (ERRs), particularly ERRγ also regulate skeletal muscle oxidative capacity, mitochondrial biogenesis, oxidative phosphorylation and oxidative slow-twitch myofiber type (16–18). Others including NR4A’s (19–21), liver X receptors (22–24), Rev-erb’s (25, 26) and estrogen (27) receptors have recently been implicated in regulating various aspects of metabolism in the skeletal muscle.
In contrast to their role in metabolic regulation, the function of nuclear receptors in skeletal muscle vascularization has been examined only for a handful of receptors. Pharmacology studies show that PPAR agonists can promote muscle angiogenesis in hindlimb ischemia (HLI) (28–32); however, evidence that these agonists elicit angiogenic effects by activating PPARs in the skeletal muscle is lacking. Androgen receptors in the skeletal muscle promotes paracrine angiogenesis and ischemic revascularization (33). Our recent work demonstrated that ERRγ can mitigate muscle ischemia and muscular dystrophy in part by increasing angiogenic gene expression and muscle vascularization (34, 35). Muscle-centric role of most other nuclear receptors remains unexplored in regulation of skeletal muscle angiogenesis, and thus presents an opportunity for advancing discoveries that could promote vascularization in the ischemic skeletal muscle.
In this study, we have investigated the role of muscle ERRα in skeletal muscle angiogenesis. Previous studies suggest that ERRα might contribute to skeletal muscle angiogenesis. For example, in global ERRα knockout mice exercise-induced increase in skeletal muscle capillary staining is decreased (36). Furthermore, ERRα regulates Vegfa gene expression in cultured cells (37). However, the contribution of muscle ERRα in driving functional skeletal muscle vascularization has not been examined. Similarly, the precise angiogenic gene program activated by ERRα in the skeletal muscle beyond Vegfa is unclear. More critically, ERRα’s involvement in promoting ischemic vascular recovery including restoration of skeletal muscle perfusion has not been measured. Here we report that ERRα is an ischemia/hypoxia-induced factor, and its transgenic overexpression in the skeletal muscle stimulates a pro-angiogenic gene program that increases skeletal muscle angiogenesis, and facilitates revascularization in a murine model of hindlimb ischemia (HLI).
MATERIAL & METHODS
Mouse husbandry
Generation of muscle-specific ERRα transgenic (TG) mice is described below. ERRα floxed mice have been described before (38), and were generously provided by Dr. Janice Huss (City of Hope). Muscle-specific human alpha skeletal actin driven Cre recombinase transgenic mice (HSA-Cre, B6.Cg-Tg (ACTA1-cre) 79Jme/J) were obtained from The Jackson Laboratory. Muscle-specific ERRα knockout mice were generated by crossing the ERRα floxed and HSA-Cre mice. All the mice were housed in a temperature-controlled room (20-22 °C) with ad libitum access to water and food (Pico Lab rodent diet 20; 13.2% fat) under a 12:12 h light dark cycle. Experiments were performed in 3-4 months old male mice. For adeno-associated virus-mediated overexpression studies 3 months old male C57Bl/6J mice (Jackson labs) were used. Animals were maintained and treated in accordance with the U.S. National Institute of Health Guide for Care and Use of Laboratory Animals; and the procedures were approved by the Animal Welfare Committee at The University of Texas Health Science Center in Houston.
Hypoxia and drug treatment in C2C12 Cells
Murine C2C12 muscle cells (CRL1772 from ATCC, Manassas, VA) were cultured in DMEM with 10% FBS and Normocin (Invitrogen, Carlsbad, CA). For the differentiation of C2C12 cells into myotubes, 10% FBS media was replaced with DMEM containing 2% horse serum when the cells were ~90% confluent. Five day differentiated C2C12 cells were subjected to hypoxia in the Modular Incubator Chamber. A gas mixture of 5% CO2 and 95% N2 was flushed through the Modular Incubator Chamber containing the cultured cells at a flow rate of 20 liters/min for 5 min. The chamber containing the cells in the hypoxic environment were maintained in the regular cell culture incubator at 37°C for 6 hr. For hypoxia mimetic studies, the cells were treated with 1 mM Dimethyloxaloylglycine (DMOG) for 24 hr. or 200 μM Cobalt chloride (CoCl2) for 12 hr. For HIF1α inhibition the 4 day differentiated cells were pre-treated for 24 hr. with 10 μM PRLX 93936 (# 25631, Cayman, Ann Arbor, MI), and for HIF2α inhibition with 50 μM of HIF-2α translation inhibitor (# 40087, Millipore Sigma, Burlington, MA) followed by 6 hr. of hypoxia. The cells were subsequently collected and processed for western blotting.
Generation of muscle-specific ERRα TG Mice
Muscle-specific ERRα TG mice were generated using transgene containing muscle-specific human alpha skeletal actin promoter and mouse ERRα cDNA using standard transgenesis techniques. The ERRα coding sequence was cloned in pBSK-HSA plasmid at EcoRI and BamHI sites followed by cloning of bovine growth hormone poly-adenylation signal sequence at Not I site at the 3’ end of ERRα. The transgene construct was sequenced to confirm presence of all components in the appropriate sequence, and subsequently excised from pBSK-HSA-ERRα plasmid by digesting with PciI and PsiI restriction enzymes. The transgene DNA was microinjected into fertilized oocytes of F1 mice (C57BL/6J). Screening of founder mice and their offspring for stable transmission through the germline was performed by PCR. These mice were generated in the transgenic core laboratory at UTHealth. Age and sex-matched wild type C57Bl/6J littermates of the transgenic mice were used as controls. The littermate control mice do not harbor the transgene or the copy of the empty vector.
Tissue collection and preparation
Mice were euthanized by isoflurane inhalation followed by cervical dislocation and tissues were rapidly extracted. For RNA and protein analysis, muscles were freeze-clamped in liquid nitrogen. For immunofluorescence, TA muscles were mounted in OCT and frozen on melting isopentane in liquid nitrogen.
RNA Sequencing & Data Analysis
For RNA Sequencing analysis (RNA-Seq), total RNA from WT, and TG gastrocnemius were extracted with Purelink Kit (Ambion, Life technologies, Carlsbad, CA), and was further reverse-transcribed to cDNA with SuperScript III Reverse Transcriptase (Invitrogen, Waltham, MA). Poly (A)-tailed mRNA was enriched and the RNA-seq library was prepared in the UT Cancer Genomics Center by following the instructions in KAPA mRNA HyperPrep Kit (KK8581, Roche, Holding AG, Switzerland) and KAPA Unique Dual-indexed Adapter kit (KK8727, Roche). RNA-seq was performed using the Illumina Nextseq550 with the 75 bp pair-ended running mode. Raw mRNA sequence reads were pre-processed using Cutadapt (v1.15) to remove bases with quality scores < 20 and adapter sequences (39), followed by alignment of clean RNA-seq reads to GRCm38 with STAR (v2.5.3a) (40). Uniquely-mapped reads overlapping genes were counted by HTseq-count with default parameter using annotation from GencodeM15. Only genes with > 5 reads in at least one sample were retained. The raw read counts of retained genes were submitted for differential expression analysis of cases compared to controls with DESeq2 software (41), which uses a model based on the negative binomial distribution. Resulting p-values were adjusted using the Benjamini and Hochberg’s approach (42) to control for false discovery rate (FDR). Genes with fold change (FC) > 1.5 (or FC < 0.667) and FDR < 0.05 were assigned as differentially expressed genes (DEGs). Standard gene set enrichment analysis was performed with a hypergeometric test using WebGestalt (v 0.4.3) (43). The resulting p-values were also adjusted using the Benjamini and Hochberg’s approach (42).
Gene expression
Quantitative real-time PCR (qPCR) analysis was performed using SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA) with a BioRad XF96 cycler (BioRad, Hercules, CA) using cDNA reverse transcribed from mRNA of WT and TG gastrocnemius (N=3-5). Primer sequences are shown in Supplemental Data Unit 1. All data were normalized to TBP and Hsp90.
Western immunoblotting
Gastrocnemius from WT and TG mice were homogenized in RIPA buffer (Thermo Scientific, Waltham, MA) using Tissue Lyser (Qiagen, Hilden, Germany) at speed 50, three cycles of 1 minute followed by centrifugation at 12,000 g for 15 min at 4 °C. The Pierce BCA protein assay kit (Thermo Scientific) was used to quantify protein in supernatant, which was then stored at −80 °C. Samples were separated by SDS-PAGE, transferred onto nitrocellulose membrane, stained using Ponceau S, blocked with 5% milk in phosphate buffered saline with 0.1% Tween20 (PBST), and incubated overnight at 4 °C with primary antibodies, AMPK (#2532), p-AMPK (#2535), ERRα (# 13826), DLL4 (# 96406), and eNOS (# 9586) all at 1:1000 (Cell signaling, Danvers, MA); VEGFR2 at 1:1000 (# MA5-15157, Invitrogen, Carlsbad, CA); VEGFA (# sc-7269) at 1:250, and Myoglobin (#sc-74525) at 1:500 (Santa Cruz Biotechnology, Dallas, TX). Membranes were then washed with PBST and incubated with the appropriate secondary antibodies (Cell Signaling) for 1 hr. at room temperature, washed with PBST, and bands visualized using chemiluminescence western blotting detection reagents.
Immunohistology
Cryosections (10 μm) were obtained from mid-section of tibialis anterior (TA) muscle from WT and TG mice. Myosin heavy chains (MHC) type 2A and 2B were stained using the mouse monoclonal antibodies SC71 (5 μg/ml) and BF.F3 (4 μg/ml), respectively (Developmental Studies Hybridoma Bank, Iowa City, IA), as we previously described (34). Laminin was stained using antibody L9393 from Sigma, St. Louis, MO at 3.5 μg/ml dilution to visualize sarcolemma. Capillaries, pericytes, and smooth muscles/arterioles were stained using CD31 (# MCA2388) at 10 μg/ml (Bio-Rad, Hercules, CA), NG2-Cy3 (# AB5320C3) at 10 ug/ml (Sigma, St. Louis, MO), and αSMA (# A5228) at 10 μg/ml (Sigma, St. Louis, MO), respectively. All primary antibodies were visualized using suitable Alexa Fluor® secondary antibodies from Molecular Probes, Eugene, OR. Immunostained sections were examined using confocal microscopy. Myofiber number was counted using Amira software version 6.3 from FEI Hillsboro, OR. CD31, NG2, and αSMA densitometry was performed using ImageJ.
Nicotinamide Adenine Dinucleotide (NADH)-Tetrazolium Reductase (TR) Staining
NADH-TR staining was performed on 10 μm TA cryosections from WT and TG mice. Briefly, the cryosections were incubated at 37°C for 30 min in substrate buffer [0.05 M Tris-HCl buffer pH 7.4 containing NADH (8 mg/10ml) and NBT (10 mg/10 ml)]. Sections were then washed three times with water followed by 2 min washes with increasing and decreasing concentrations of acetone (30%, 60%, and 90%). Finally, the sections were washed three times with water and mounted in an aqueous mounting media and visualized under light microscope.
ERRα Reporter Gene Assay
ERRα and HIF1α reporter gene assay was performed as previously described (34). Briefly, HEK 293T cells were plated in 96-well plates and cultured in DMEM supplemented with 10% FBS and 0.2% Normocine to reach 90% confluence. Cells were transfected with the Vegfa promoter-driven firefly luciferase (100 ng) along with a control plasmid (pCMX, 80 ng), ERRα plasmid (pCMX-ERRα, 80 ng), or HIF1α plasmid (# sc119189, Origene Rockville, MD, 80 ng) using lipofectamine 3000, according to the manufacturer’s instructions (Invitrogen). Control renilla luciferase plasmid was included in all transfections for normalization. After 24 hr. of transfection chemiluminescence measurement was performed using the Dual-Glo Luciferase Assay System (Promega).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed in 5 days differentiated C2C12 cells using the Simple ChIP Enzymatic Chromatin IP Kit (# 9003S, Cell Signaling) following manufacturer’s instructions. Briefly, two 15 cm plates were combined per sample. Cells were fixed, washed, and lysed using 40 strokes of Dounce homogenizer B. Chromatin was then digested using 1 μl of enzyme per sample for 20 min at 37°C. It was further sonicated two times for 10 sec each. Part of the digested chromatin was saved for 2% input and for confirming effective digestion. The remaining digested chromatin was split into two equal halves and incubated overnight at 4°C with either 5 μg of ERRα antibody (# 13826, Cell Signaling) or 5 ug of control rabbit IgG along with 45 μl of protein G magnetic beads. The beads were washed and further processing was carried out as per the kit protocol to obtain de-crosslinked purified input, ChIP-IgG, and ChIP-ERRα chromatin. QPCR was performed for promoter region of several genes using primer pairs as shown in Supplemental Data Unit 1. Percent enrichment for ChIP-IgG and ChIP-ERRα was obtained relative to input. Data are represented as fold enrichment for ChIP-ERRα relative to its ChIP-IgG.
Adeno-associated virus 9-mediated intramuscular ERRα overexpression
AAV9-Esrra virus was obtained from VectorBuilder Inc., Chicago, IL. These studies were performed in 3 months old C57Bl/6J male mice. For intramuscular injections, 5 μl of virus (in PBS) was injected into the TA in 3 different regions for a total of 15 μl containing 2×1011 AAV9-Esrra viral particles. The contralateral leg TA was injected in a similar fashion with empty vector control. Both the TAs were collected after 10 days. One half of each TA was flash frozen in liquid nitrogen for gene expression analysis. The other half was frozen in OCT for sectioning and 10 μm TA sections were immuno-stained for CD31, and enzymatically stained for NADH-TR activity, as described above. Following sectioning, the residual TA was removed from OCT and processed for the measurement of ERRα protein expression by western blotting.
Microfil or microsphere perfusion and whole mount vascular imaging
WT and TG mice were anesthetized by intraperitoneal injection of 100 mg/kg Ketamine (Ketathesia) and 10 mg/kg of Xylazine (Anased) (Henry Schein, Melville, NY). Anesthetized mice were perfused with PBS by intra-cardiac route followed by administration of either a 16% (w/v) microfil pigment solution of gouache in 4% PFA, or 1:10 diluted 0.1 μm fluorescent microspheres (# F8801, Invitrogen, Carlsbad, CA) in PBS. In the microfil perfused mice the muscles were dissected, followed by serial dehydration by immersing for 1 day each in 25%, 50%, 75%, 95% and 100% ethanol. Next, the tissues were incubated in fresh transparency solution that consisted of 1:1 benzylbezoate and benzylalcohol until tissues became transparent in approximately 12 hr. After the muscles were processed, whole-mount images of the muscle vasculature were obtained using an inverted bright field microscope. For visualization of fluorescent microspheres TA was collected and frozen in OCT followed by sectioning and imaging using confocal microscopy.
Hindlimb ischemia, tissue collection, and laser Doppler blood flowmetry
Hindlimb ischemia was induced in WT and TG mice by unilateral femoral vessel occlusion, as we previously described (34, 44). In this model, ischemia is induced in left hindlimb, and the contralateral right hindlimb serves as the control. TA muscles were harvested at indicated time-points after the induction of ischemia and processed for immunohistology. Mice were anesthetized, as described above, and blood flow was measured in both the contralateral and ischemic flexor digitorum brevis muscle from WT and TG mice with a deep tissue laser Doppler flow probe (PeriFlux system 5000, Perimed, Sweden). Blood perfusion in the ischemic hindlimb muscle is reported as the percent of perfusion in contralateral non-ischemic hindlimb muscle (Ischemic limb perfusion x 100/contralateral limb perfusion).
Statistics
Unpaired Student’s t-test, one-way ANOVA and two-way repeated measure ANOVA with appropriate post-hoc tests were used as indicated in the figure legends to compare the different groups. Data in figures is presented as mean ± standard error of mean (SEM), and p<0.05 is considered as statistically significant. Power analysis estimated that N used in each experiment was sufficient to achieve a power of 0.8 and Type 1 error rate of 5%. Data were analyzed and plotted using GraphPad Prism 5. The analysis of RNA-seq data is described above.
RESULTS
Muscle ERRα is induced by ischemia in a HIF-dependent fashion in the skeletal muscle
As a first step to appraise the potential role of ERRα in muscle ischemia, we measured the effect of hindlimb ischemia (HLI) on muscle ERRα expression. We induced unilateral HLI in wild type (WT) mice and measured ERRα protein expression in ischemic and contralateral TA 7 day after HLI. Ischemia significantly induced ERRα protein expression in the TA (Figure 1A). To confirm that the induction of ERRα in muscle lysates is from change occurring in the myofibers, we repeated the same experiment in WT and muscle-specific ERRα knockout mice (MEAKO). These mice were generated by crossing ERRα floxed mice (38) with HSA-Cre mice, and littermate ERRα floxed mice were used as control. While HLI induced muscle ERRα expression in WT mice, the receptor expression was undetectable in both the control and ischemic TA of MEAKO mice (Supplemental Data Unit 2A). Interestingly, 6-48 hr. of fasting also induced ERRα expression in the TA, suggesting that ischemic induction of ERRα could be partly linked to nutrient deprivation (Supplemental Data Unit 2B).
Figure 1. Induction of ERRα by ischemia and hypoxia.

(A-D) Representative western blots showing ERRα expression in murine tibialis anterior (TA) and 5 day differentiated C2C12 cells along with densitometric analysis. ERRα expression in: (A) contralateral and ischemic TA 7 days after HLI (N=3); (B) Normoxic and hypoxic (6 hr.) C2C12 cells (N=6); (C) Vehicle or CoCl2 (200 μM, 12 hr.) treated C2C12 cells (N=6); and (D) Vehicle or DMOG (1 mM, 24 hr.) treated C2C12 cells (N=6). (E-F) Hypoxic induction of ERRα in C2C12 cells in presence and absence of HIF1α inhibitor (PRLX-93936, 10μM) (E) and HIF2α translational inhibitor (50 μM) (F) (N=6). P<0.05 = *, p<0.01 = **, and p<0.001= ***. Unpaired Student’s t-test or one-way ANOVA with Dunnett’s post-hoc analysis.
In in vitro experiments, we examined the effect of hypoxia on ERRα expression in differentiated muscle C2C12 myotubes. These cells were subjected to hypoxia (95% nitrogen, 5% CO2) or normoxia (air with 5% CO2) for 6 hr., following which ERRα protein expression was measured. We previously reported that similar hypoxic stimulation of muscle cells was sufficient to induce angiogenic factors such as Vegfa (34, 44). Under these conditions, hypoxia significantly induced ERRα expression in differentiated muscle C2C12 cells (Figure 1B). Given the central role of hypoxia inducible factors (HIF) in hypoxic cellular response, we investigated whether ERRα induction by hypoxia involves HIF in muscle cells. First, we measured the effect of HIF activators CoCl2 (200 μM) and DMOG (1 mM) on ERRα expression in C2C12 cells. We found that both CoCl2 and DMOG significantly increased ERRα expression (Figure 1C–D). Second, ERRα expression was measured in differentiated C2C12 myotubes subjected to hypoxia in the presence or absence of HIF1α or HIF2α inhibitors. We found that inhibition of HIF1α by PRLX-93936 pre-treatment (12 hr. at 10 μM) blocked the hypoxic induction of ERRα (Figure 1E). Similarly, inhibition of HIF2α by pre-treatment with HIF2α translational inhibitor (12 hr. at 50 μM) attenuated hypoxic induction of ERRα (Figure 1F). We scanned the ERRα gene promoter region (up to 1600 kbs upstream of transcriptional start sit) using JASPAR 2020 transcription factor motif database, which predicated 12 putative HIF1A::ARNT response elements in this region. The two top ranked sites were at positions −676 (CCACGTGG) and −984 (CGGCGTGG). These data suggest that ERRα could be involved in hypoxic or ischemic muscle response. Further, HIF pathway is involved in the hypoxic induction of ERRα, potentially through transcriptional regulation of the receptor expression.
Generation of skeletal muscle-specific ERRα overexpressing transgenic mice
To investigate the potential ameliorative role of muscle ERRα signaling in skeletal muscle ischemic response, we generated muscle-specific ERRα overexpressing transgenic mice (TG). The ERRα transgene expression was driven in a skeletal muscle-specific fashion using a human skeletal alpha actin (HSA) promoter (Figure 2A, left panel) (45). Transgenesis resulted in a higher expression of ERRα protein in the skeletal muscles of TG vs. WT mice, as shown in the TA (Figure 2A, right panel). Overexpression of ERRα in the TG muscle results in a phenotypically redder musculature compared to WT (Figure 2B), which is generally indicative of oxidative/fiber type remodeling. Cross-sectional analysis for NADH-TR (mitochondrial complex I enzyme) activity, a classical marker of mitochondrial oxidative capacity, showed an increase in oxidative myofibers in TG compared to WT TA (Figure 2C). To measure the shift in fiber type we performed myofiber type analysis using MHC antibody staining. ERRα overexpression increased the proportion of oxidative fast-twitch type 2A and type 2X, and decreased glycolytic fast-twitch type 2B myofibers (Figure 2D–E) in the TA. In concert, quantitative real-time PCR (qPCR) and western blotting analysis showed that ERRα overexpression induced the expression of both mRNA (such as Cycs, Ppara, myoglobin, and Ucp3) (Figure 2F) and protein (such as myoglobin and p-AMPK) (Figure 2G) biomarkers of oxidative muscle in TG compared to the WT gastrocnemius. Higher expression of ERRα transcript in TG compared to WT muscle is also shown (Figure 2F). These data confirm that muscle-specific transgenesis results in overexpression of a transcriptionally active ERRα, which drives oxidative metabolic remodeling in the skeletal muscle.
Figure 2. Generation of muscle-specific ERRα overexpressing mice.

(A) Left panel. Illustration of transgene containing ERRα cDNA driven by human alpha-skeletal actin (HSA) promoter. Right panel. Representative western blot of ERRα protein expression in tibialis anterior (TA) of transgenic (TG) vs. wild type (WT) mice. (B) Representative images of musculature comparing TG vs. WT mice. Black arrows indicate redder phenotype in TG vs. WT muscles. (C) Representative TA cryosections stained for NADH-TR activity (blue) comparing TG and WT mice (N=4). (D-E) Representative TA cryosections from WT and TG mice showing type 2A (green), 2X (unstained) and 2B (red) myofibers (D) and their quantification (E) (N=4). Scale bars in (C) and (D) = 500 μm. (F) qPCR quantification of oxidative and fiber type genes in gastrocnemius of WT and TG mice (N=5). (G) Representative western blots and densitometry of myoglobin, p-AMPK, and t-AMPK protein expression in TG and WT gastrocnemius (N=5). P<0.05= *, p<0.01= **, and p<0.001= ***. Unpaired Student’s t-test.
ERRα transcriptome analysis identifies angiogenic genes as top-ranked up-regulated pathway in the skeletal muscle
To identify potential ERRα transcriptomic pathways that might be involved in ischemic muscle response we performed RNA-seq analysis on gastrocnemius from TG and WT mice. A total of 188.9 million clean reads were generated in 8 samples between TG and WT mice. After data filtering, the qualified reads were mapped to GRCm38 with average reads unique mapping ratio at 80.5%. Genes with 1.5-fold change or greater and FDR <0.05 were regarded as differentially expressed genes (DEG). By these criteria, we identified 3292 DEG in the transgenic muscles, out of which 1577 genes were upregulated and 1715 genes were downregulated by ERRα (Figure 3A). We focused our attention on positively regulated genes to identify gene targets of ERRα that could play a positive role in ischemic response. The upregulated genes were subjected to functional enrichment analyses using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations using the WebGestaltR software (43). The top 30 most significantly enriched pathways are shown in Figure 3B. Strikingly, the enrichment analysis revealed that genes associated with angiogenesis regulation (GO: 0001525) were the topmost ranked pathway among the upregulated gene sets. Heatmap depicting the upregulation of angiogenesis-linked genes by ERRα is shown in Figure 3C. The top 30 significantly enriched pathways also included fatty acid metabolism (GO: 0006631) and degradation (GO: 1901342), which consisted several known gene targets of ERRα in the muscle (Supplemental Data Unit 3A and B). Upregulation of fatty acid metabolic genes by ERRα is in concert with the oxidative phenotype observed in Figure 2. The identification of angiogenic gene set as a major pathway activated by ERRα overexpression supports the likelihood that this receptor plays a role in skeletal muscle vascularization.
Figure 3. Transcriptomic changes in ERRα overexpressing skeletal muscle.

(A) Volcano plot from RNA-seq analysis of TG vs. WT gastrocnemius showing differentially expressed genes with 1.5-fold change and false discovery rate (FDR) < 0.05 (N=4). (B) Functional enrichment analysis of the upregulated gene sets in TG muscle using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations showing top 30 gene sets including the 1st ranked angiogenesis gene set (GO: 0001525). (C) Heat map showed the up-regulation (Z-score scaled) of angiogenesis-linked genes in TG vs. WT muscles.
ERRα overexpression promotes angiogenic gene expression and vascularization in the skeletal muscle
To substantiate the result that ERRα regulates angiogenic genes in the skeletal muscle, we subjected mRNA isolated from TG and WT gastrocnemius to qPCR analysis. Several pro-angiogenic genes (identified in RNA-seq analysis) were inducted by ERRα in gastrocnemius (Figure 4A). Since the TG muscles exhibit increased pro-angiogenic gene expression, we measured whether ERRα overexpression promotes skeletal muscle vascularization. Endothelial immunostaining of TA cryosections using CD31 antibody revealed higher capillarity in TG compared to WT TA (Figure 4B). We also observed higher immunofluorescence staining of αSMA in TG compared to WT TA cryosections, indicating higher number of arterioles (Figure 4C). To determine whether ERRα facilitates formation of intact blood vessels, we perfused TG and WT mice with fluorescently-labeled microspheres (0.1 μm) which get entrapped in non-leaky blood vessels. Fluorescence imaging of microsphere signals from TA cryosections show increase in non-leaky blood vessels in TG compared to WT muscles suggesting that ERRα promotes formation of intact blood vessels (Figure 4D). Coimmunostaining for CD31 (endothelial cells) and NG2 (pericytes) (Figure 4E) demonstrate co-localization of endothelial cells and pericytes in both the WT and TG TA. CD31 densitometry in TG TA increased by 52.32% compared to WT TA (N=4 mice, WT = 6913.13 ± 292.76, TG = 10530.12 ± 435.39 p=0.0003, Unpaired Student’s t-test). Similarly, NG2 densitometry in TG TA increased by 53.18% compared to WT TA (N=4 mice, WT = 8397.21 ± 775.77, TG = 12863.49 ± 1189.67 p=0.0131, Unpaired Student’s t-test). These data indicate a simultaneous increase in endothelial cells as well as pericytes in transgenic mice, with close to 100% association of endothelial cells with pericytes. Changes in skeletal muscle vascular supply was also confirmed by measuring the expression of vascular markers. Compared to WT, TG muscles express significantly higher levels of DLL4, VEGFR2, and eNOS, which are endothelial markers (Figure 4F–G). We also quantified PDGFRβ, which is a pericyte marker that surrounds fully matured blood vessels, and found that it is significantly higher in TG compared to WT TA (Figure 4F–G). Increase in expression of vascular markers in the TG muscle coincides with higher expression of VEGFA protein (Figure 4F–G). Collectively, these data demonstrate that ERRα overexpression promotes angiogenic factors expression leading to increased vascularization of the skeletal muscle.
Figure 4. ERRα overexpression promotes skeletal muscle vascularization.

(A) QPCR analysis of candidate pro-angiogenic genes in TG vs. WT gastrocnemius (N=5). (B-C) Representative images of tibialis anterior (TA) cryosections immunostained for CD31 (B) and αSMA (C), respectively showing higher capillary and arteriole/smooth muscle staining in TG compared to WT mice (N=4). (D) Representative images of fluorescent microsphere-perfused TA cryosections showing greater perfusion in TG vs. WT muscles (N=4). (E) Representative images of CD31 and NG2 immunostained TA showing co-localization of the endothelial cells and pericytes (N=4). Red scale bars in (B-E) = 100 μm. (F) Representative western blots showing expression of vascular proteins (DLL4, VEGFR2, eNOS, and PDGFRβ) and VEGFA in WT and TG gastrocnemius. (G) Densitometry of protein expression in (E) (N=5). P<0.05 = *, p<0.01 = **, and p<0.001 = ***. Unpaired Student’s t-test.
To validate the phenotypic changes obtained by transgenic ERRα overexpression in the skeletal muscle we used an alternative approach of intramuscular AAV9-Esrra gene delivery. A robust overexpression of ERRα in TA was achieved by intramuscular injection of AAV9-Esrra (2 × 1011 viral particles) (Supplemental Data Unit 4A, Left Panel), measured 10 days after virus injection. Overexpression of ERRα transformed the TA to a redder phenotype compared to the contralateral control TA (Supplemental Data Unit 4A, Right Panel). CD31 immunostaining revealed that AAV9-Esrra injection significantly increased capillary staining compared to control TA (Supplemental Data Unit 4B). Similarly, NADH-TR staining was significantly increased in oxidative fibers in AAV9-Esrra injected TA compared to the contralateral muscle (Supplemental Data Unit 4C). AAV9-Esrra mediated overexpression of ERRα also increased the expression of metabolic as well as angiogenic genes in the TA (Supplemental Data Unit 4D). These data collectively show that transient virus-mediated overexpression of ERRα recapitulates transgenic overexpression in inducing pro-oxidative and pro-angiogenic changes in the skeletal muscle.
ERRα is directly recruited to angiogenic gene promoters
Examination of murine genomic sequences (up to 2000 kb upstream of transcriptional start sites) revealed that several of the angiogenic genes induced by ERRα such as Angpt1, Egf, Epas1, and Vegfa contain potential ERRα response elements in the promoter region (Figure 5A). ChIP-qPCR using primers designed to amplify regions inclusive of these sites showed enrichment of ERRα in angiogenic gene promoters in muscle C2C12 myotubes (Figure 5B). ERRα was also enriched at known metabolic target genes such as Cycs, Pdk4, and myoglobin in muscle C2C12 myotubes (Figure 5A and C). We further used Vegfa promoter cloned into a pGL3 luciferase vector (17) to demonstrate that ERRα can directly activate this promoter in a fashion similar to HIF1A in a reporter gene assay (Figure 5D). These data indicate that ERRα can directly regulate angiogenic gene expression via promoter regulation.
Figure 5. ERRα enrichment at angiogenic gene promoters.

(A) Potential ERRα response elements in promoter region (up to −2000 kb with reference to the transcriptional start site +1) of target genes. (B) ChIP-qPCR in 5 days differentiated C2C12 myotubes demonstrating ERRα enrichment at representative angiogenic (B) as well as metabolic (C) gene promoters. N=6 biological replicates with technical duplicates. (C) Reporter gene assay demonstrating ERRα and HIF1A-mediated activation of Vegfa gene promoter (N=3 biological replicates with technical quadruplicates). P<0.05 = *, P<0.001 = ***. One-way ANOVA with Dunnett’s post-hoc analysis.
ERRα overexpression facilitates ischemic neo-angiogenesis and restores muscle perfusion in HLI
The above results raise the possibility that ERRα can facilitate angiogenesis and revascularization of the skeletal muscle in response to surgically-induced HLI. Therefore, we subjected the WT and TG mice to unilateral HLI by performing femoral vessel ligation and transection in the left limb and using contralateral leg as a control, to determine the effect of ERRα overexpression on muscle perfusion recovery over 25 days post-surgery. Capillary staining using CD31 antibody 7 days post-surgery showed that ischemia induced capillarization in WT TA (Figure 6A, left panel). This effect was significantly increased in the TG TA (Figure 6A, right panel) compared to WT. The quantification of muscle capillary density is shown in Figure 6B. αSMA immunostaining for detecting arteries/arterioles showed that the formation of new arteries was greater in TG TA than in WT TA 24 days post-HLI (Figure 6C). Quantification of αSMA staining showed that TG TA generally exhibited higher arteriole density compared to WT TA, with maximum arteriole density observed in ischemic TG TA (Figure 6D).We further performed microfil perfusion of the mice at 14 days post-HLI followed by whole mount imaging of various hindlimb muscles to visualize dye-perfused blood vessels in hindlimb musculature. We found that while TG muscles had higher baseline perfusion compared to WT, it was further enhanced in TG muscles in response to ischemic insult (Figure 6E). Finally, we measured blood flow recovery in the flexor digitorum brevis (FDB) muscle of the footpad, which is the distal most muscle from the HLI site, using laser Doppler flowmetry. We observed that the blood perfusion in TG ischemic footpad recovered faster compared to the WT ischemic footpad, with restoration of perfusion within 18-22 days post-ischemia in the transgenic mice (Figure 6F). Notably, ischemia did not further induce ERRα or Vegfa expression in the transgenic muscle over the induction achieved by the ERRα transgene (Supplemental Data Unit 5). These results point to the possibility that ERRα overexpression is involved in vascular recovery in hindlimb ischemia, potentially due to baseline remodeling of the skeletal muscle.
Figure 6. ERRα overexpression promotes muscle revascularization in HLI.

(A) Representative CD31 (capillary) immunostaining of WT and TG tibialis anterior (TA) from contralateral and ischemic legs, 7 days after hindlimb ischemia (HLI). Scale bars=100 μm. (B) Quantification of (A) (N=3). (C) Representative αSMA immunostaining of WT and TG TA from contralateral and ischemic legs 24 days after hindlimb ischemia (HLI). Scale bars = 250 μm. (D) Quantification of (C) (N=6). (E) Representative images of microfil-perfused hindlimb muscles 14 days after HLI, comparing TG and WT mice (N=3). (Soleus=S; Plantaris=P; Tibialis Anterior=TA; Gastrocnemius=Ga; and Quadriceps=Qd.) (F) Laser Doppler flowmetry measuring time-course of muscle perfusion after HLI in TG and WT mice. (N=9-10). P<0.05 = *, p<0.01 = **, p<0.001 = ***, p<0.0001=****. One-way ANOVA with Tukey’s multiple comparison test (B) and two-way repeated measure ANOVA with Bonferroni post-hoc test (F). (G) Schematic model. ERRα is induced by hypoxia or ischemia in the skeletal muscle in HIF-dependent fashion. ERRα overexpression triggers a dual program of oxidative metabolism and angiogenesis in the skeletal muscle, and facilitates ischemic revascularization in hindlimb ischemia. The ERRα effects in the muscle may involve direct and indirect gene regulatory mechanisms.
DISCUSSION
In this study we examined the role of muscle ERRα in promoting angiogenesis and revascularization in skeletal muscle ischemia. We show that alongside driving oxidative metabolic program, ERRα overexpression activates a comprehensive angiogenic gene program in the skeletal muscle that increases skeletal muscle vascularity. More importantly, ERRα overexpression facilitates ischemic angiogenesis and vascular regeneration in the skeletal muscle restoring perfusion in hindlimb ischemia. Therefore, muscle ERRα could be potentially involved in muscle angiogenesis, and could be therapeutically targeted in aging and diabetes-associated vascular complications such as PAD or CLI, where vascular insufficiency and muscle ischemia is a common pathology (Figure 6G).
The first indication that ERRα might be involved in ischemic response in the skeletal muscle was the observation that it was induced by hypoxia and hypoxia-mimetic agents in cultured muscles cells, as well as by HLI in the murine skeletal muscles. Notably, our data from the muscle-specific ERRα knockout mice suggest that ischemic induction of ERRα occurs primarily in the skeletal muscle cells. Furthermore, ERRα induction by starvation suggests that nutrient deprivation induced by hindlimb ischemia may be a critical driver of ERRα in the skeletal muscle. In cultured muscle cells, the induction of ERRα is dependent on HIF, as its expression is increased by HIF stabilizers, and its induction by hypoxia is blocked by HIF1α and HIF2α inhibitors. The HIF-response elements found in the ERRα gene promoter region suggests a role for transcriptional regulation in HIF-dependent induction of ERRα. Notably, ERR isoforms are also shown to physically interact with HIF1α, HIF2α and HIF1β, albeit in non-muscle cells (46). Inhibition of ERR’s also seems to impair HIF-mediated gene expression (46). Another study in drosophila shows that while dERRα interacts with dHIF (d, drosophila) in mediating some of the transcriptional effects of dHIF in response to hypoxia, dERR can additionally mediate HIF-independent effect of hypoxia via metabolic gene regulation (47). Therefore, it is likely that these two pathways converge at both the transcriptional and post-translational levels in orchestrating the ischemic/hypoxic response in the mammalian skeletal muscle.
To examine the role of muscle ERRα in hindlimb ischemia, we generated muscle-specific ERRα overexpressing mice. In these mice, ERRα increased oxidative capacity as indicated by overall redder appearance of the musculature, detected by increased NADH-TR activity as well as induction of aerobic biomarkers. These results are in conjugation with various studies linking ERRα and oxidative metabolism in the skeletal muscle. ERRα global knockout mice have distorted skeletal muscle gene signature, with decreased expression of genes linked to fatty acid transport and metabolism, oxidative metabolism and redox homeostasis (16). Several cellular studies have also identified ERRα as the mediator of oxidative metabolic gene regulation by various transcriptional co-regulators such as PGC1α, PGC1β and NCoR1 in skeletal muscle cells (48–52). Nevertheless, the effect of ERRα on skeletal muscle fiber type composition in terms of type 1 or 2 specification was previously not defined. Our data shows that ERRα increases the proportion of oxidative fast-twitch type 2A and 2X, while suppressing glycolytic fast-twitch type 2B myofibers. This is notable because our previous work suggested that fiber-type switch to oxidative myofibers such as type 2A and 2X facilitates angiogenesis and ischemic vascular recovery in the skeletal muscle (34).
RNA-seq and pathway enrichment analysis of the ERRα transcriptome in the skeletal muscle revealed that angiogenesis was the top-most pathway activated by ERRα overexpression in the skeletal muscle. This gene set contained several pro-angiogenesis factors including Fgf1, Vegfa, Epas1, Angptl, Cxcl12, Igf2, Nrp1, Nrp2, Angpt4, Lrg1, Cxcr4 and Nos3. While, ERRα was previously reported to regulate Vegfa and Nos3 expression (33, 37, 53, 54), other angiogenic factors to our knowledge were not known to be ERRα targets. Our targeted ChIP-qPCR experiment suggests that at least a subset of these genes is regulated by direct enrichment of ERRα at the promoter. A comprehensive ChIP-seq experiment would be subsequently necessary to identify the complete roster of direct and indirect angiogenic gene targets of ERRα in the skeletal muscle. Several of these candidate genes are paracrine factors (e.g. Fgf1, Vegfa, Angptl, Cxcl12, Igf2, Angpt4, and Lrg1) that activate angiogenesis in endothelial cells (53, 55–60), highlighting a muscle-to-endothelial crosstalk controlled by muscle ERRα in driving vascularization. ERRα may also interact with other signaling pathways (e.g. Epas1, Hdac7, Nos3) to mediate muscle angiogenesis and vascular integrity (61–63). While we have directly focused on angiogenesis factors in the skeletal muscle, other ERRα-activated gene programs in the top 30 list included leucocyte activation and migration, leukocyte adhesion, cell-cell adhesion, as well as regulation of inflammatory response. These pathways could also mediate the effects of ERRα by regulating the recruitment of immune cells such as macrophages that are involved in ischemic muscle recovery (64, 65).
The collective activation of various gene sets by ERRα overexpression that directly or indirectly regulate angiogenesis is potentially advantageous compared to the therapeutic application of individual angiogenic factors in PAD. Indeed, ERRα overexpression results in the formation of non-leaky mature vasculature measured using microsphere or microfil angiography. Immunohistology analysis showed that ERRα is promoting capillary as well as arteriole growth, along with vessel maturation as indicated by increase in expression markers such as PDGFRβ (66), as well as increased αSMA (smooth muscle cell marker) and NG2 staining (pericyte marker). ERRα overexpression also facilitated neo-angiogenesis in the ischemic muscle and accelerated revascularization and reperfusion in the hindlimbs. Ischemia did not further induce ERRα or Vegfa expression in the transgenic muscle over the induction achieved by the ERRα transgene. Therefore, improved re-vascularization in the current transgenic mouse model could to be linked to baseline remodeling of the skeletal muscle by ERRα prior to ischemia. Therefore, future additional studies will be needed to determine the efficacy of post-ischemic ERRα activation in promoting neo-angiogenesis and revascularization in the skeletal muscle through generation of inducible transgenic mice and/or use of AAV9-mediated delivery. Notably, our experiments with AAV9-Essra indicate that localized intramuscular delivery of ERRα can trigger angiogenic gene expression and capillarization in non-ischemic muscle, raising the likelihood that post-ischemic activation of ERRα could be beneficial in promoting revascularization. Furthermore, the overlap in the angiogenic effects of ERRα and ERRγ (34) in the skeletal muscle is particularly interesting. In vitro studies suggest that ERR’s can regulate transcription as homo or heterodimers (67–70). Whether such heterodimerization plays a role in muscle vascularization by ERR’s remains to be determined in the skeletal muscle. Overall, it can be envisioned that pan-ERR activation via pharmacological or gene therapy approaches could provide an effective strategy for treating PAD in the future.
ERRα is ubiquitously expressed, and its effects via other cell types may also contribute to fine-tuning the resolution of hindlimb ischemia. For example, we showed in cultured endothelial cells that ERRα limits excessive activation of angiogenesis by angiogenic factors (71), an effect that could be critical for preventing immature blood vessel formation in vivo. In immune cells, particularly in macrophages, ERRα drives an anti-inflammatory gene program that could also be critical for resolving skeletal muscle ischemia (72–74). Furthermore, ERRα can promote myogenesis and muscle regeneration (38, 75), which could contribute to recovery from ischemic injury. Gain and/or loss-of-function studies to examine the relative contributions of ERRα in different cell types to ischemic muscle recovery could provide novel insights into multi-cellular transcriptional mechanisms through which ERRα activation in ischemia could be beneficial. In conclusion, we showed that ERRα is a hypoxia-stimulated factor, which in turn activates a paracrine angiogenic gene program to promote normal as well as ischemic neo-angiogenesis in the skeletal muscle, and presents an emerging opportunity for treating vascular complications such as PAD and CLI.
Supplementary Material
ACKNOWLEDGEMENTS
We would like to thank Dr. Janice Huss (City of Hope) for generously providing us with the ERRα floxed mice.
FUNDING SOURCE
This research was supported by funding to V.A.N from NIH (#1R01HL129191), Bayer Pharmaceuticals (#0014079), American Heart Association (20TPA35410038) and Hamman Foundation Endowment in Cardiovascular Research. D.H.S. was supported by a post-doctoral fellowship from American Heart Association (#19POST34380771). V.Y. was supported by Ramalingaswami Department of Biotechnology, Government of India Fellowship (#BT/RLF/Re-entry/29/2014). Z.Z. is supported by NIH grant # R01LM012806. RNA sequencing and data analysis work was performed through the UTHealth Cancer Genomics Core funded by Cancer Prevention and Research Institute of Texas (CPRIT) core grant (#RP180734). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Nonstandard abbreviations
- PAD
Peripheral arterial disease
- CLI
Critical Limb Ischemia
- ERRα
Estrogen-related receptor alpha
- HLI
Hindlimb ischemia
- HIF
Hypoxia inducible factor
- VEGFA
Vascular endothelial growth factor alpha
- FGF1
Fibroblast growth factor 1
- PPAR
Peroxisome proliferator-activated receptor
- NR4A
Nuclear receptor subfamily 4 group A
- DMOG
Dimethyloxaloylglycine
- FDR
False discovery rate
- DEG
Differentially expressed genes
- AMPK
5’ adenosine monophosphate-activated protein kinase
- DLL4
Delta like canonical notch ligand 4
- eNOS
Endothelial nitric oxide synthase
- VEGFR2
Vascular endothelial growth factor receptor 2
- TA
Tibialis anterior
- MHC
Myosin heavy chain
- CD31
Cluster of differentiation 31
- αSMA
Alpha smooth muscle actin
- Cycs
Cytochrome c somatic
- Ucp3
Uncoupling protein 3
- PDGFRβ
Platelet-derived growth factor receptor beta
- GO
Gene ontology
- KEGG
Kyoto encyclopedia of genes and genomes
Footnotes
CONFLICTS OF INTEREST
The authors declare that they have no conflict of interest.
REFERENCES
- 1.Hiatt WR, Armstrong EJ, Larson CJ, and Brass EP (2015) Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. Circ Res 116, 1527–1539 [DOI] [PubMed] [Google Scholar]
- 2.Hamburg NM, and Creager MA (2017) Pathophysiology of Intermittent Claudication in Peripheral Artery Disease. Circ J 81, 281–289 [DOI] [PubMed] [Google Scholar]
- 3.Jude EB, Eleftheriadou I, and Tentolouris N (2010) Peripheral arterial disease in diabetes--a review. Diabet Med 27, 4–14 [DOI] [PubMed] [Google Scholar]
- 4.Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, and Criqui MH (2017) Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol 14, 156–170 [DOI] [PubMed] [Google Scholar]
- 5.Bonaca MP, and Creager MA (2015) Pharmacological treatment and current management of peripheral artery disease. Circ Res 116, 1579–1598 [DOI] [PubMed] [Google Scholar]
- 6.Schiaffino S, and Reggiani C (2011) Fiber types in mammalian skeletal muscles. Physiol Rev 91, 1447–1531 [DOI] [PubMed] [Google Scholar]
- 7.Thyfault JP, and Booth FW (2011) Lack of regular physical exercise or too much inactivity. Curr Opin Clin Nutr Metab Care 14, 374–378 [DOI] [PubMed] [Google Scholar]
- 8.Kelley DE (2005) Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest 115, 1699–1702 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Matsakas A, and Narkar VA (2010) Endurance exercise mimetics in skeletal muscle. Curr Sports Med Rep 9, 227–232 [DOI] [PubMed] [Google Scholar]
- 10.Kupr B, Schnyder S, and Handschin C (2017) Role of Nuclear Receptors in Exercise-Induced Muscle Adaptations. Cold Spring Harb Perspect Med 7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Gan Z, Burkart-Hartman EM, Han DH, Finck B, Leone TC, Smith EY, Ayala JE, Holloszy J, and Kelly DP (2011) The nuclear receptor PPARbeta/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev 25, 2619–2630 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, and Evans RM (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2, e294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, Desvergne B, Wahli W, Chambon P, and Metzger D (2006) PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 4, 407–414 [DOI] [PubMed] [Google Scholar]
- 14.Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, and Kelly DP (2005) A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 1, 133–144 [DOI] [PubMed] [Google Scholar]
- 15.Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, Dohm GL, Yan Z, Newgard CB, and Muoio DM (2005) Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 280, 33588–33598 [DOI] [PubMed] [Google Scholar]
- 16.Perry MC, Dufour CR, Tam IS, B’Chir W, and Giguere V (2014) Estrogen-related receptor-alpha coordinates transcriptional programs essential for exercise tolerance and muscle fitness. Molecular endocrinology 28, 2060–2071 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Narkar VA, Fan W, Downes M, Yu RT, Jonker JW, Alaynick WA, Banayo E, Karunasiri MS, Lorca S, and Evans RM (2011) Exercise and PGC-1alpha-independent synchronization of type I muscle metabolism and vasculature by ERRgamma. Cell Metab 13, 283–293 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Rangwala SM, Wang X, Calvo JA, Lindsley L, Zhang Y, Deyneko G, Beaulieu V, Gao J, Turner G, and Markovits J (2010) Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity. The Journal of biological chemistry 285, 22619–22629 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Tontonoz P, Cortez-Toledo O, Wroblewski K, Hong C, Lim L, Carranza R, Conneely O, Metzger D, and Chao LC (2015) The orphan nuclear receptor Nur77 is a determinant of myofiber size and muscle mass in mice. Mol Cell Biol 35, 1125–1138 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Amoasii L, Sanchez-Ortiz E, Fujikawa T, Elmquist JK, Bassel-Duby R, and Olson EN (2019) NURR1 activation in skeletal muscle controls systemic energy homeostasis. Proc Natl Acad Sci U S A 116, 11299–11308 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Pearen MA, Goode JM, Fitzsimmons RL, Eriksson NA, Thomas GP, Cowin GJ, Wang SC, Tuong ZK, and Muscat GE (2013) Transgenic muscle-specific Nor-1 expression regulates multiple pathways that effect adiposity, metabolism, and endurance. Mol Endocrinol 27, 1897–1917 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Cozzone D, Debard C, Dif N, Ricard N, Disse E, Vouillarmet J, Rabasa-Lhoret R, Laville M, Pruneau D, Rieusset J, Lefai E, and Vidal H (2006) Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 49, 990–999 [DOI] [PubMed] [Google Scholar]
- 23.Kase ET, Wensaas AJ, Aas V, Hojlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, and Gaster M (2005) Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 54, 1108–1115 [DOI] [PubMed] [Google Scholar]
- 24.Muscat GE, Wagner BL, Hou J, Tangirala RK, Bischoff ED, Rohde P, Petrowski M, Li J, Shao G, Macondray G, and Schulman IG (2002) Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors. J Biol Chem 277, 40722–40728 [DOI] [PubMed] [Google Scholar]
- 25.Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, and Burris TP (2012) Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485, 62–68 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MK, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Neviere R, Burris TP, Schrauwen P, Staels B, and Duez H (2013) Rev-erb-alpha modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 19, 1039–1046 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ribas V, Drew BG, Zhou Z, Phun J, Kalajian NY, Soleymani T, Daraei P, Widjaja K, Wanagat J, de Aguiar Vallim TQ, Fluitt AH, Bensinger S, Le T, Radu C, Whitelegge JP, Beaven SW, Tontonoz P, Lusis AJ, Parks BW, Vergnes L, Reue K, Singh H, Bopassa JC, Toro L, Stefani E, Watt MJ, Schenk S, Akerstrom T, Kelly M, Pedersen BK, Hewitt SC, Korach KS, and Hevener AL (2016) Skeletal muscle action of estrogen receptor alpha is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. Sci Transl Med 8, 334ra354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Khazaei M, Salehi E, Rashidi B, Javanmard SH, and Fallahzadeh AR (2012) Role of peroxisome proliferator-activated receptor beta agonist on angiogenesis in hindlimb ischemic diabetic rats. J Diabetes Complications 26, 137–140 [DOI] [PubMed] [Google Scholar]
- 29.Li P, Shibata R, Maruyama S, Kondo M, Ohashi K, Ouchi N, and Murohara T (2010) Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. Am J Physiol Endocrinol Metab 299, E560–566 [DOI] [PubMed] [Google Scholar]
- 30.Salehi E, Khazaei M, and Rashidi B (2012) Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats. Gen Physiol Biophys 31, 255–260 [DOI] [PubMed] [Google Scholar]
- 31.Ashoff A, Qadri F, Eggers R, Johren O, Raasch W, and Dendorfer A (2012) Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression. J Vasc Res 49, 260–266 [DOI] [PubMed] [Google Scholar]
- 32.Nagahama R, Matoba T, Nakano K, Kim-Mitsuyama S, Sunagawa K, and Egashira K (2012) Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 32, 2427–2434 [DOI] [PubMed] [Google Scholar]
- 33.Yoshida S, Aihara K, Ikeda Y, Sumitomo-Ueda Y, Uemoto R, Ishikawa K, Ise T, Yagi S, Iwase T, Mouri Y, Sakari M, Matsumoto T, Takeyama K, Akaike M, Matsumoto M, Sata M, Walsh K, Kato S, and Matsumoto T (2013) Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation 128, 60–71 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Matsakas A, Yadav V, Lorca S, Evans RM, and Narkar VA (2012) Revascularization of ischemic skeletal muscle by estrogen-related receptor-gamma. Circ Res 110, 1087–1096 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Matsakas A, Yadav V, Lorca S, and Narkar V (2013) Muscle ERRgamma mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27, 4004–4016 [DOI] [PubMed] [Google Scholar]
- 36.Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, Sawada N, Raghuram S, and Arany Z (2009) The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci U S A 106, 21401–21406 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Stein RA, Gaillard S, and McDonnell DP (2009) Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol 114, 106–112 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.LaBarge S, McDonald M, Smith-Powell L, Auwerx J, and Huss JM (2014) Estrogen-related receptor-alpha (ERRalpha) deficiency in skeletal muscle impairs regeneration in response to injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 28, 1082–1097 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 [Google Scholar]
- 40.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Anders S, and Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11, R106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Benjamini Y, and Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Statist Soc B 57, 289–300 [Google Scholar]
- 43.Liao Y, Wang J, Jaehnig EJ, Shi Z, and Zhang B (2019) WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res 47, W199–W205 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Yadav V, Matsakas A, Lorca S, and Narkar VA (2014) PGC1beta activates an antiangiogenic program to repress neoangiogenesis in muscle ischemia. Cell reports 8, 783–797 [DOI] [PubMed] [Google Scholar]
- 45.Muscat GE, and Kedes L (1987) Multiple 5’-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression. Molecular and cellular biology 7, 4089–4099 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Ao A, Wang H, Kamarajugadda S, and Lu J (2008) Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. Proc Natl Acad Sci U S A 105, 7821–7826 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Li Y, Padmanabha D, Gentile LB, Dumur CI, Beckstead RB, and Baker KD (2013) HIF- and non-HIF-regulated hypoxic responses require the estrogen-related receptor in Drosophila melanogaster. PLoS Genet 9, e1003230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Nagai H (1987) [Midwifery practice of Ainu. 4. Narrow pelvis and protection of the perineal region]. Josanpu Zasshi 41, 602–603 [PubMed] [Google Scholar]
- 49.Perez-Schindler J, Summermatter S, Salatino S, Zorzato F, Beer M, Balwierz PJ, van Nimwegen E, Feige JN, Auwerx J, and Handschin C (2012) The corepressor NCoR1 antagonizes PGC-1alpha and estrogen-related receptor alpha in the regulation of skeletal muscle function and oxidative metabolism. Mol Cell Biol 32, 4913–4924 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Huss JM, Torra IP, Staels B, Giguere V, and Kelly DP (2004) Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Molecular and cellular biology 24, 9079–9091 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, Sihag S, Yang W, Altshuler D, Puigserver P, Patterson N, Willy PJ, Schulman IG, Heyman RA, Lander ES, and Spiegelman BM (2004) Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A 101, 6570–6575 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Kamei Y, Ohizumi H, Fujitani Y, Nemoto T, Tanaka T, Takahashi N, Kawada T, Miyoshi M, Ezaki O, and Kakizuka A (2003) PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci U S A 100, 12378–12383 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Yang Q, Wang P, Du X, Wang W, Zhang T, and Chen Y (2018) Direct repression of IGF2 is implicated in the anti-angiogenic function of microRNA-210 in human retinal endothelial cells. Angiogenesis 21, 313–323 [DOI] [PubMed] [Google Scholar]
- 54.Sumi D, and Ignarro LJ (2003) Estrogen-related receptor alpha 1 up-regulates endothelial nitric oxide synthase expression. Proc Natl Acad Sci U S A 100, 14451–14456 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Cooke JP, and Losordo DW (2015) Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res 116, 1561–1578 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Salcedo R, and Oppenheim JJ (2003) Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10, 359–370 [DOI] [PubMed] [Google Scholar]
- 57.Saharinen P, Eklund L, and Alitalo K (2017) Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov 16, 635–661 [DOI] [PubMed] [Google Scholar]
- 58.Geretti E, and Klagsbrun M (2007) Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr 1, 56–61 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Hato T, Tabata M, and Oike Y (2008) The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 18, 6–14 [DOI] [PubMed] [Google Scholar]
- 60.Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, Luhmann UFO, Lange CAK, Zhai Z, Arthur HM, Bainbridge J, Moss SE, and Greenwood J (2013) LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499, 306–311 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Chang S, Young BD, Li S, Qi X, Richardson JA, and Olson EN (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126, 321–334 [DOI] [PubMed] [Google Scholar]
- 62.Takeda N, Maemura K, Imai Y, Harada T, Kawanami D, Nojiri T, Manabe I, and Nagai R (2004) Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 95, 146–153 [DOI] [PubMed] [Google Scholar]
- 63.Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N, Ogihara T, Kaneda Y, Kohno M, and Morishita R (2003) Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 108, 2250–2257 [DOI] [PubMed] [Google Scholar]
- 64.Shireman PK (2007) The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 45 Suppl A, A48–56 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Sass FA, Fuchs M, Pumberger M, Geissler S, Duda GN, Perka C, and Schmidt-Bleek K (2018) Immunology Guides Skeletal Muscle Regeneration. Int J Mol Sci 19 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Winkler EA, Bell RD, and Zlokovic BV (2010) Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener 5, 32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Huppunen J, and Aarnisalo P (2004) Dimerization modulates the activity of the orphan nuclear receptor ERRgamma. Biochem Biophys Res Commun 314, 964–970 [DOI] [PubMed] [Google Scholar]
- 68.Horard B, Castet A, Bardet PL, Laudet V, Cavailles V, and Vanacker JM (2004) Dimerization is required for transactivation by estrogen-receptor-related (ERR) orphan receptors: evidence from amphioxus ERR. J Mol Endocrinol 33, 493–509 [DOI] [PubMed] [Google Scholar]
- 69.Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavailles V, and Laudet V (1999) Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). Mol Endocrinol 13, 764–773 [DOI] [PubMed] [Google Scholar]
- 70.Hentschke M, Susens U, and Borgmeyer U (2002) Domains of ERRgamma that mediate homodimerization and interaction with factors stimulating DNA binding. Eur J Biochem 269, 4086–4097 [DOI] [PubMed] [Google Scholar]
- 71.Likhite N, Yadav V, Milliman EJ, Sopariwala DH, Lorca S, Narayana NP, Sheth M, Reineke EL, Giguere V, and Narkar V (2019) Loss of Estrogen-Related Receptor Alpha Facilitates Angiogenesis in Endothelial Cells. Mol Cell Biol 39 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Kim SY, Yang CS, Lee HM, Kim JK, Kim YS, Kim YR, Kim JS, Kim TS, Yuk JM, Dufour CR, Lee SH, Kim JM, Choi HS, Giguere V, and Jo EK (2018) ESRRA (estrogen-related receptor alpha) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense. Autophagy 14, 152–168 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Yuk JM, Kim TS, Kim SY, Lee HM, Han J, Dufour CR, Kim JK, Jin HS, Yang CS, Park KS, Lee CH, Kim JM, Kweon GR, Choi HS, Vanacker JM, Moore DD, Giguere V, and Jo EK (2015) Orphan Nuclear Receptor ERRalpha Controls Macrophage Metabolic Signaling and A20 Expression to Negatively Regulate TLR-Induced Inflammation. Immunity 43, 80–91 [DOI] [PubMed] [Google Scholar]
- 74.Michalek RD, Gerriets VA, Nichols AG, Inoue M, Kazmin D, Chang CY, Dwyer MA, Nelson ER, Pollizzi KN, Ilkayeva O, Giguere V, Zuercher WJ, Powell JD, Shinohara ML, McDonnell DP, and Rathmell JC (2011) Estrogen-related receptor-alpha is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci U S A 108, 18348–18353 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Murray J, and Huss JM (2011) Estrogen-related receptor alpha regulates skeletal myocyte differentiation via modulation of the ERK MAP kinase pathway. Am J Physiol Cell Physiol 301, C630–645 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
